BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33612403)

  • 1. Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria.
    Castner LM; Zimbric M; Cahalan S; Powell C; Caverly LJ
    J Cyst Fibros; 2021 Nov; 20(6):926-931. PubMed ID: 33612403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis.
    VanDevanter EJ; Heltshe SL; Skalland M; Lechtzin N; Nichols D; Goss CH
    J Cyst Fibros; 2021 Nov; 20(6):932-936. PubMed ID: 33685776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment.
    Cogen JD; Sanders DB; Slaven JE; Faino AV; Somayaji R; Gibson RL; Hoffman LR; Ren CL
    Ann Am Thorac Soc; 2023 Sep; 20(9):1293-1298. PubMed ID: 37327485
    [No Abstract]   [Full Text] [Related]  

  • 4. Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
    Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nichols DP; Rosenfeld M; Gibson RL
    Clin Infect Dis; 2021 Nov; 73(9):1589-1596. PubMed ID: 34100912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis.
    McElvaney OJ; Heltshe SL; Odem-Davis K; West NE; Sanders DB; Fogarty B; VanDevanter DR; Flume PA; Goss CH
    Ann Am Thorac Soc; 2024 May; 21(5):716-726. PubMed ID: 38096105
    [No Abstract]   [Full Text] [Related]  

  • 6. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
    Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
    J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment.
    Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Kronman MP; Rosenfeld M; Nichols DP
    Ann Am Thorac Soc; 2021 Feb; 18(2):266-272. PubMed ID: 32810412
    [No Abstract]   [Full Text] [Related]  

  • 8. Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
    Davis CS; Faino AV; Onchiri F; Gibson RL; Merjaneh L; Ramsey BW; Rosenfeld M; Cogen JD
    Ann Am Thorac Soc; 2023 Jan; 20(1):75-82. PubMed ID: 36044723
    [No Abstract]   [Full Text] [Related]  

  • 9. Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations.
    Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nelson M; Nichols DP; Rosenfeld M; VanDevanter DR; Gibson RL
    Ann Am Thorac Soc; 2020 Dec; 17(12):1590-1598. PubMed ID: 32726564
    [No Abstract]   [Full Text] [Related]  

  • 10. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.
    West NE; Beckett VV; Jain R; Sanders DB; Nick JA; Heltshe SL; Dasenbrook EC; VanDevanter DR; Solomon GM; Goss CH; Flume PA;
    J Cyst Fibros; 2017 Sep; 16(5):600-606. PubMed ID: 28457954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF.
    Heltshe SL; West NE; VanDevanter DR; Sanders DB; Beckett VV; Flume PA; Goss CH;
    Contemp Clin Trials; 2018 Jan; 64():35-40. PubMed ID: 29170074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis.
    Wagener JS; VanDevanter DR; Konstan MW; Pasta DJ; Millar SJ; Morgan WJ
    Pediatr Pulmonol; 2020 Mar; 55(3):828-834. PubMed ID: 31746561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations.
    Heltshe SL; Russell R; VanDevanter DR; Sanders DB
    J Cyst Fibros; 2023 Sep; 22(5):864-867. PubMed ID: 36803635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymicrobial infections and antibiotic treatment patterns for cystic fibrosis pulmonary exacerbations.
    Faino AV; Hoffman LR; Gibson RL; Kronman MP; Nichols DP; Rosenfeld M; Cogen JD
    J Cyst Fibros; 2023 Jul; 22(4):630-635. PubMed ID: 36849332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotics and outcomes of CF pulmonary exacerbations in children infected with MRSA and Pseudomonas aeruginosa.
    Cogen JD; Hall M; Faino AV; Ambroggio L; Blaschke AJ; Brogan TV; Cotter JM; Gibson RL; Grijalva CG; Hersh AL; Lipsett SC; Shah SS; Shapiro DJ; Neuman MI; Gerber JS
    J Cyst Fibros; 2023 Mar; 22(2):313-319. PubMed ID: 35945130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
    Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
    Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of pulmonary exacerbation treatment in cystic fibrosis.
    Sanders DB; Ostrenga JS; Rosenfeld M; Fink AK; Schechter MS; Sawicki GS; Flume PA; Morgan WJ
    J Cyst Fibros; 2020 May; 19(3):407-414. PubMed ID: 31257102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations.
    Zemanick ET; Harris JK; Wagner BD; Robertson CE; Sagel SD; Stevens MJ; Accurso FJ; Laguna TA
    PLoS One; 2013; 8(4):e62917. PubMed ID: 23646159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic beta-lactam dosages and broad-spectrum antibiotics are associated with reductions in microbial richness and diversity in persons with cystic fibrosis.
    Hahn A; Burrell A; Chaney H; Sami I; Koumbourlis AC; Freishtat RJ; Crandall KA; Zemanick ET
    Sci Rep; 2023 Jan; 13(1):1217. PubMed ID: 36681756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients.
    Worlitzsch D; Rintelen C; Böhm K; Wollschläger B; Merkel N; Borneff-Lipp M; Döring G
    Clin Microbiol Infect; 2009 May; 15(5):454-60. PubMed ID: 19196263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.